These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
191 related articles for article (PubMed ID: 26362858)
1. Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells. Li H; Kong X; Cui G; Ren C; Fan S; Sun L; Zhang Y; Cao R; Li Y; Zhou J Int J Hematol; 2015 Nov; 102(5):558-68. PubMed ID: 26362858 [TBL] [Abstract][Full Text] [Related]
2. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells. Bishop JD; Nien WL; Dauphinee SM; Too CK J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Ikezoe T; Nishioka C; Bandobashi K; Yang Y; Kuwayama Y; Adachi Y; Takeuchi T; Koeffler HP; Taguchi H Leuk Res; 2007 May; 31(5):673-82. PubMed ID: 17007924 [TBL] [Abstract][Full Text] [Related]
5. The Akt/mTOR/p70S6K pathway is activated in IgA nephropathy and rapamycin may represent a viable treatment option. Tian J; Wang Y; Guo H; Li R Exp Mol Pathol; 2015 Dec; 99(3):435-40. PubMed ID: 26297427 [TBL] [Abstract][Full Text] [Related]
6. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Han S; Khuri FR; Roman J Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245 [TBL] [Abstract][Full Text] [Related]
7. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains]. Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057 [TBL] [Abstract][Full Text] [Related]
8. Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia. Li J; Xue L; Hao H; Han Y; Yang J; Luo J Oncol Rep; 2012 Feb; 27(2):461-6. PubMed ID: 21993902 [TBL] [Abstract][Full Text] [Related]
9. Akirin2 could promote the proliferation but not the differentiation of duck myoblasts via the activation of the mTOR/p70S6K signaling pathway. Sun W; Huang H; Ma S; Gan X; Zhu M; Liu H; Li L; Wang J Int J Biochem Cell Biol; 2016 Oct; 79():298-307. PubMed ID: 27590857 [TBL] [Abstract][Full Text] [Related]
10. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia. Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465 [TBL] [Abstract][Full Text] [Related]
11. Influence of carboplatin on the proliferation and apoptosis of ovarian cancer cells through mTOR/p70s6k signaling pathway. Zhou H; Zhao H; Liu H; Xu X; Dong X; Zhao E J BUON; 2018; 23(6):1732-1738. PubMed ID: 30610801 [TBL] [Abstract][Full Text] [Related]
12. Effect of rapamycin treatment in human seminoma TCam-2 cells through inhibition of G1-S transition. Onel T; Erdogan CS; Aru B; Yildirim E; Demirel GY; Yaba A Naunyn Schmiedebergs Arch Pharmacol; 2023 May; 396(5):1009-1018. PubMed ID: 36598515 [TBL] [Abstract][Full Text] [Related]
13. Activation of the AKT and mammalian target of rapamycin pathways and the inhibitory effects of rapamycin on those pathways in canine malignant melanoma cell lines. Kent MS; Collins CJ; Ye F Am J Vet Res; 2009 Feb; 70(2):263-9. PubMed ID: 19231960 [TBL] [Abstract][Full Text] [Related]
14. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR. Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108 [TBL] [Abstract][Full Text] [Related]
15. Expression of the miR-150 tumor suppressor is restored by and synergizes with rapamycin in a human leukemia T-cell line. Podshivalova K; Wang EA; Hart T; Salomon DR Leuk Res; 2018 Nov; 74():1-9. PubMed ID: 30269036 [TBL] [Abstract][Full Text] [Related]
16. Rapamycin inhibits mTOR/p70S6K activation in CA3 region of the hippocampus of the rat and impairs long term memory. Lana D; Di Russo J; Mello T; Wenk GL; Giovannini MG Neurobiol Learn Mem; 2017 Jan; 137():15-26. PubMed ID: 27838442 [TBL] [Abstract][Full Text] [Related]
17. Role of AMP-activated protein kinase activators in antiproliferative multi-drug pituitary tumour therapies: effects of combined treatments with compounds affecting the mTOR-p70S6 kinase axis in cultured pituitary tumour cells. Tulipano G; Faggi L; Cacciamali A; Spinello M; Cocchi D; Giustina A J Neuroendocrinol; 2015 Jan; 27(1):20-32. PubMed ID: 25323047 [TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells. Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092 [TBL] [Abstract][Full Text] [Related]
19. Rapamycin reverses NPM-ALK-induced glucocorticoid resistance in lymphoid tumor cells by inhibiting mTOR signaling pathway, enhancing G1 cell cycle arrest and apoptosis. Gu L; Gao J; Li Q; Zhu YP; Jia CS; Fu RY; Chen Y; Liao QK; Ma Z Leukemia; 2008 Nov; 22(11):2091-6. PubMed ID: 18685609 [TBL] [Abstract][Full Text] [Related]
20. [The relationship of mTOR signaling pathway and histone acetylation in human gastric cancer cell lines]. Sun DF; Fang JY; Zhang YJ; Tian XQ; Zhu HY; Li EL; Gu WQ; Shen GF Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):387-91. PubMed ID: 17680526 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]